CN1314681C - 具有血管生成抑制活性的2,3－二氮杂萘衍生物 - Google Patents

具有血管生成抑制活性的2,3－二氮杂萘衍生物 Download PDF

Info

Publication number
CN1314681C
CN1314681C CNB028092937A CN02809293A CN1314681C CN 1314681 C CN1314681 C CN 1314681C CN B028092937 A CNB028092937 A CN B028092937A CN 02809293 A CN02809293 A CN 02809293A CN 1314681 C CN1314681 C CN 1314681C
Authority
CN
China
Prior art keywords
compound
formula
tautomer
mixture
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028092937A
Other languages
English (en)
Chinese (zh)
Other versions
CN1507444A (zh
Inventor
G·博尔德
P·W·曼利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1507444A publication Critical patent/CN1507444A/zh
Application granted granted Critical
Publication of CN1314681C publication Critical patent/CN1314681C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB028092937A 2001-05-04 2002-05-03 具有血管生成抑制活性的2,3－二氮杂萘衍生物 Expired - Fee Related CN1314681C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0111078.2 2001-05-04
GBGB0111078.2A GB0111078D0 (en) 2001-05-04 2001-05-04 Organic compounds

Publications (2)

Publication Number Publication Date
CN1507444A CN1507444A (zh) 2004-06-23
CN1314681C true CN1314681C (zh) 2007-05-09

Family

ID=9914117

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028092937A Expired - Fee Related CN1314681C (zh) 2001-05-04 2002-05-03 具有血管生成抑制活性的2,3－二氮杂萘衍生物

Country Status (12)

Country Link
US (3) US7399761B2 (https=)
EP (1) EP1387836B1 (https=)
JP (1) JP4365586B2 (https=)
CN (1) CN1314681C (https=)
AT (1) ATE393152T1 (https=)
BR (1) BR0209332A (https=)
CA (1) CA2446051A1 (https=)
DE (1) DE60226225T2 (https=)
ES (1) ES2301648T3 (https=)
GB (1) GB0111078D0 (https=)
PT (1) PT1387836E (https=)
WO (1) WO2002090346A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1712234B1 (en) * 2001-09-12 2009-01-28 Novartis AG Use of 4-Pyridylmethylphthalazines for Renal Cancer Treatment
WO2004002485A1 (en) * 2002-06-28 2004-01-08 Novartis Ag Combination comprising a vasculostatic compound and an alkylating agent for the treatmemt of a tumor
EP1738752A1 (en) * 2002-12-27 2007-01-03 Schering Aktiengesellschaft Pharmaceutical combinations comprising cis-retine acid
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
EP1919906B1 (en) * 2005-08-29 2011-10-12 Vertex Pharmaceuticals Incorporated 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
RU2522444C2 (ru) 2008-08-27 2014-07-10 Лео Фарма А/С Производные пиридина в качестве ингибиторов рецепторов фактора роста эндотелия сосудов 2 подтипа (vegfr-2) и протеинтирозинкиназы
JP6088063B2 (ja) * 2012-11-16 2017-03-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトン型チロシンキナーゼの阻害剤
JP6282721B2 (ja) 2013-03-14 2018-02-21 ダート・ニューロサイエンス・（ケイマン）・リミテッド Ｐｄｅ４阻害剤としての置換ピリジン及びピラジン化合物
JP2024505256A (ja) * 2021-01-28 2024-02-05 ユニバーシティ オブ フロリダ リサーチファウンデーション インコーポレイティッド 神経変性、変性及び代謝性障害の処置のための化合物並びにその使用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0722936A1 (en) * 1994-08-09 1996-07-24 Eisai Co., Ltd. Fused pyridazine compound
WO1998035958A1 (en) * 1997-02-13 1998-08-20 Novartis Ag Phthalazines with angiogenesis inhibiting activity
WO2000059509A1 (en) * 1999-03-30 2000-10-12 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
WO2001010859A1 (en) * 1999-08-10 2001-02-15 Bayer Corporation Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE567431A (https=) 1957-05-07
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
US4665181A (en) * 1984-05-17 1987-05-12 Pennwalt Corporation Anti-inflammatory phthalazinones
JPH03106875A (ja) 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
EP0600831A1 (de) 1992-11-27 1994-06-08 Ciba-Geigy Ag Phthalazinonderivate
MY117098A (en) 1996-01-15 2004-05-31 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0722936A1 (en) * 1994-08-09 1996-07-24 Eisai Co., Ltd. Fused pyridazine compound
WO1998035958A1 (en) * 1997-02-13 1998-08-20 Novartis Ag Phthalazines with angiogenesis inhibiting activity
WO2000059509A1 (en) * 1999-03-30 2000-10-12 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
WO2001010859A1 (en) * 1999-08-10 2001-02-15 Bayer Corporation Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity

Also Published As

Publication number Publication date
US8034814B2 (en) 2011-10-11
GB0111078D0 (en) 2001-06-27
WO2002090346A1 (en) 2002-11-14
US20110130399A1 (en) 2011-06-02
ATE393152T1 (de) 2008-05-15
EP1387836A1 (en) 2004-02-11
ES2301648T3 (es) 2008-07-01
US7399761B2 (en) 2008-07-15
JP2004532241A (ja) 2004-10-21
DE60226225D1 (de) 2008-06-05
PT1387836E (pt) 2008-06-27
BR0209332A (pt) 2004-07-20
EP1387836B1 (en) 2008-04-23
DE60226225T2 (de) 2009-09-10
US20090076003A1 (en) 2009-03-19
CN1507444A (zh) 2004-06-23
US20040180899A1 (en) 2004-09-16
JP4365586B2 (ja) 2009-11-18
CA2446051A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
CN1324022C (zh) 酪氨酸激酶抑制剂
CN100345830C (zh) 稠合杂芳基衍生物
CN1284783C (zh) 作为p38蛋白激酶抑制剂的取代的含氮杂环
CN1247567C (zh) 2－氨基－3－烷基嘧啶酮衍生物作为GSK3β抑制剂
US8664246B2 (en) Substituted pyridines, and use thereof as GSK3 inhibitors
CN1703414A (zh) 用作细胞周期蛋白依赖性激酶抑制剂的新颖咪唑并吡啶
CN1701073A (zh) 作为细胞周期蛋白依赖激酶抑制剂的吡唑并[1,5－a]嘧啶
CN1191239C (zh) 用于治疗病毒性疾病的吡唑衍生物
CN1906190A (zh) 选择性激酶抑制剂
CN1769283A (zh) 具有血管生成抑制活性的取代的吡啶和哒嗪
CN1444563A (zh) 喹啉和喹唑啉衍生物
CN1922185A (zh) 作为激酶抑制剂的吡唑并三嗪类化合物
CN1684951A (zh) 新的嘧啶胺衍生物及其用途
CN1882578A (zh) 作为zap－70和/或syk抑制剂的2,4－二(杂)芳基氨基嘧啶衍生物
CN101065016A (zh) 蛋白激酶的抑制剂咪唑并[4,5－b]吡嗪酮
CN1882591A (zh) 具有PDE－5抑制活性的5,7－二氨基吡唑并[4,3－d]嘧啶
CN1701074A (zh) 用作依赖细胞周期蛋白激酶抑制剂的吡唑并嘧啶
CN1694708A (zh) TGFβ的抑制剂
CN101039914A (zh) 作为激酶抑制剂的三氟甲基取代的苯甲酰胺化合物
CN101031560A (zh) 用作酪氨酸激酶抑制剂的环状二芳基脲
CN1267432C (zh) 2－吡啶基－6,7,8,9－四氢嘧啶并[1,2－a]嘧啶－4－酮和7－吡啶基－2,3－二氢咪唑并[1,2－a]嘧啶－5(1H)酮衍生物
CN1509291A (zh) 噁唑并嘧啶和呋喃并嘧啶化合物以及它们作为抗肿瘤药物的用途
CN1347416A (zh) 取代的3－氰基－[1.7],[1.5]和[1.8]－二氮杂萘酪氨酸激酶抑制剂
CN1681816A (zh) 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并吡啶
CN1032648C (zh) 一种血小板活化因子拮抗剂的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070509

Termination date: 20130503